The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
Official Title: Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study
Study ID: NCT04653740
Brief Summary: This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
Detailed Description: Patients enrolled in the study will receive the following interventions: * Biospecimen sample collection: before and during treatment, and at progression * Tumor biopsy before treatment and at progression The aim of this study is to describe molecular changes associated with resistance to Palbociclib at the individual level and describe longitudinal changes in the profile of tumor, VOCs and exosomes according to treatment response. Other objectives of the study include: * Proportion of single or shared molecular alterations / signatures between patients at progression time * Associations between tumor signatures, VOCs and exosomes * Compare molecular changes identified by proteomics with those observed by genomics / transcriptomics * Compare the evolution of VOCs and exosomes over time with evolution of liquid biopsy markers.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Centre Oscar Lambret, Lille, , France